Alvotech (ALVO) to Release Earnings on Wednesday

Alvotech (NASDAQ:ALVO) is expected to issue its quarterly earnings data after the market closes on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.74) per share and revenue of $97.99 million for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Alvotech Trading Up 0.2 %

NASDAQ ALVO opened at $11.57 on Monday. Alvotech has a 1-year low of $9.15 and a 1-year high of $14.76. The stock has a 50-day moving average of $12.20 and a 200-day moving average of $12.18. The firm has a market cap of $3.49 billion, a PE ratio of -6.25 and a beta of -0.16.

Analyst Upgrades and Downgrades

Separately, UBS Group initiated coverage on Alvotech in a research note on Friday, February 14th. They issued a “buy” rating and a $18.00 target price for the company.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.